Dr. Lawrence E. Garbo, MD
Claim this profileNew York Oncology Hematology, P.C.
Studies Non-Small Cell Lung Cancer
Studies Gallbladder Cancer
2 reported clinical trials
4 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR positive
2Gallbladder Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Lawrence E. Garbo, MD is currently running
CTX-009 + Paclitaxel
for Biliary Tract Cancer
This trial tests a new drug (CTX-009) combined with chemotherapy in patients with advanced biliary tract cancers who have already had other treatments and cannot have surgery. The treatment aims to boost the immune system and stop cancer cell growth.
Recruiting1 award Phase 2 & 36 criteria
Reqorsa + Osimertinib
for Advanced Lung Cancer
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study will comprise of a Phase 1 dose escalation and Phase 2 evaluations of safety and efficacy. In the Phase 1 dose escalation, patients will be enrolled in sequential cohorts treated with successively higher doses of quaratusugene ozeplasmid in combination with osimertinib. When the recommended Phase 2 dose (RP2D) is determined in Phase 1, Phase 2a will be initiated and patients will be enrolled in 2 parallel, non-randomized cohorts treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.
Recruiting1 award Phase 1 & 2
More about Lawrence E. Garbo, MD
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Lawrence E. Garbo, MD has experience with
- Osimertinib
- Quaratusugene Ozeplasmid
- CTX-009
- Paclitaxel
Breakdown of trials Lawrence E. Garbo, MD has run
Non-Small Cell Lung Cancer
Gallbladder Cancer
Biliary Tract Cancer
Bile Duct Cancer
Ampullary Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lawrence E. Garbo, MD specialize in?
Lawrence E. Garbo, MD focuses on Non-Small Cell Lung Cancer and Gallbladder Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Lawrence E. Garbo, MD currently recruiting for clinical trials?
Yes, Lawrence E. Garbo, MD is currently recruiting for 2 clinical trials in Albany New York. If you're interested in participating, you should apply.
Are there any treatments that Lawrence E. Garbo, MD has studied deeply?
Yes, Lawrence E. Garbo, MD has studied treatments such as Osimertinib, Quaratusugene Ozeplasmid, CTX-009.
What is the best way to schedule an appointment with Lawrence E. Garbo, MD?
Apply for one of the trials that Lawrence E. Garbo, MD is conducting.
What is the office address of Lawrence E. Garbo, MD?
The office of Lawrence E. Garbo, MD is located at: New York Oncology Hematology, P.C., Albany, New York 12206 United States. This is the address for their practice at the New York Oncology Hematology, P.C..
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.